- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05224297
Patient Experience Data in Radiation Oncology (PEDRO)
February 23, 2022 updated by: Gerd Heilemann, Medical University of Vienna
The project is part of the overarching goal of improving patient-centric radiation oncology.
This pilot project aims to develop an instrument that can be used to collect clinically relevant patient-reported outcome data on adverse effects during and after RT.
This real-world evidence (RWE) database will be the basis to monitor and evaluate future technological developments, combination treatments (e.g.
radioimmunotherapy, etc.), or changes in treatment protocols.
The pseudonymized data will be linked to data in the oncological information system and dosimetric data from the treatment planning system.
In this way, they represent a basic building block of patient-oriented development of clinical radiotherapy.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
6000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Gerd Heilemann, PhD
- Phone Number: 004314040072710
- Email: gerd.heilemann@meduniwien.ac.at
Study Locations
-
-
-
Vienna, Austria, 1090
- Recruiting
- Medical University of Vienna
-
Contact:
- Gerd Heilemann, PhD
-
Contact:
- Andreas Renner, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 100 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The study is aimed to include a comprehensive representative cross-section for each of the study groups.
Description
Inclusion Criteria:
- all patients receiving external beam radiotherapy
Exclusion Criteria:
- unable to independently answer questionnaires on radiation-induced side effects
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
breast
|
Patients receive external beam photon therapy for different tumor locations (groups).
|
thorax
|
Patients receive external beam photon therapy for different tumor locations (groups).
|
skin
|
Patients receive external beam photon therapy for different tumor locations (groups).
|
abdomen
|
Patients receive external beam photon therapy for different tumor locations (groups).
|
skull
|
Patients receive external beam photon therapy for different tumor locations (groups).
|
head and neck
|
Patients receive external beam photon therapy for different tumor locations (groups).
|
pelvis male
|
Patients receive external beam photon therapy for different tumor locations (groups).
|
pelvis female
|
Patients receive external beam photon therapy for different tumor locations (groups).
|
extremities
|
Patients receive external beam photon therapy for different tumor locations (groups).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
radiation-related side effects
Time Frame: during radiotherapy and after (up until 5 years)
|
during radiotherapy and after (up until 5 years)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 1, 2020
Primary Completion (ANTICIPATED)
January 1, 2025
Study Completion (ANTICIPATED)
January 1, 2025
Study Registration Dates
First Submitted
January 25, 2022
First Submitted That Met QC Criteria
January 25, 2022
First Posted (ACTUAL)
February 4, 2022
Study Record Updates
Last Update Posted (ACTUAL)
March 10, 2022
Last Update Submitted That Met QC Criteria
February 23, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2184/2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PROMs
-
Istituto Ortopedico RizzoliRecruitingPROMs | Total Ankle Replacement | Italian Forgotten Joint ScoreItaly
-
Orthosensor, Inc.CompletedPatient Engagement | Knee Arthroplasty | Patient-Reported Outcome Measures (PROMs)United States
-
Assiut UniversityAO TraumaNot yet recruitingAcetabular Fracture | PROMs | Mobile Phone Use
-
Helsinki University Central HospitalRecruitingCultural Adaptation of Shoulder and Elbow PROMs | Definition of the Patients Acceptable Symptomatic State | Definition of the Minimal Important DifferenceFinland
-
Carilion ClinicNational Institutes of Health (NIH); Virginia Polytechnic Institute and State... and other collaboratorsCompletedMental Health Disorder | Telemedicine | PROMs | Waitlist | Psychiatric or Mood Diseases or ConditionsUnited States
-
Folktandvården Stockholms län ABKarolinska InstitutetCompletedPeriodontitis | Mucositis | Peri-implantitis | PROMs
-
Gazi UniversityCompletedPatellofemoral Osteoarthritis | Patellofemoral Pain Syndrome | PROMsTurkey
-
Parc de Salut MarInstituto de Salud Carlos IIIRecruitingPROMs | Implementation Research | PREMs | Impact EvaluationSpain
-
IRCCS San RaffaeleCompletedPancreatic Fistula | Complication,Postoperative | PROMs | Pancreas DiseaseItaly
-
Jessa HospitalHasselt UniversityCompletedCovid19 | PROMs | Chemotherapeutic Toxicity | OncologyBelgium
Clinical Trials on external beam photon therapy
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institute of Dental and Craniofacial...Active, not recruitingStage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7United States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingStage III Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnn Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma | Ann... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedProstate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingPain | Metastatic Malignant Neoplasm in the Bone | Malignant NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingInvasive Breast Carcinoma | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Ductal Breast Carcinoma In Situ | Stage I Breast Cancer AJCC v6United States
-
M.D. Anderson Cancer CenterActive, not recruiting
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingPSA Progression | Stage III Prostate Adenocarcinoma | Stage IV Prostate AdenocarcinomaUnited States, Canada
-
Sunnybrook Health Sciences CentreWithdrawnBone Metastases | Pathological Fracture | Lower Extremity Fracture | Impending FractureCanada